Combretastatin derivatives in cancer: Recent research reviewed

Drugs of the Future

Volumn 36, Issue 5, 2011, Pages 385-390

  Pattillo, Christopher B ^a  

^a LOUISIANA STATE UNIVERSITY HEALTH SCIENCES CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CA 432; COMBRETASTATIN; COMBRETASTATIN A1 PHOSPHATE; OMBRABULIN; ST 2151; UNCLASSIFIED DRUG; XN 0502;

APOPTOSIS; CANCER CELL CULTURE; CELL KILLING; DRUG QUALITY; DRUG STRUCTURE; HUMAN; IN VITRO STUDY; IN VIVO STUDY; NEOPLASM; REVIEW; TUMOR BLOOD FLOW; TUMOR GROWTH; TUMOR MODEL; TUMOR REGRESSION;

EID: 84952983250     PISSN: 03778282     EISSN: None     Source Type: Journal    
DOI: 10.1358/dof.2011.036.05.1590783     Document Type: Review

References (23)

1. Folkman, J. Tumor angiogenesis: therapeutic implications. N Engl J Med 1971, 285(21): 1182-6.
2. Folkman, J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med 1995, 1(1): 27-31.
3. Hamel, E., Lin, C.M. Interactions of combretastatin, a new plant-derived antimitotic agent, with tubulin. Biochem Pharmacol 1983, 32(24): 3864-7. (Pubitemid 14212219)
4. Pettit, G.R., Cragg, G.M., Singh, S.B. Antineoplastic agents, 122. Constituents of Combretum caffrum. J Nat Prod 1987, 50(3): 386-91. (Pubitemid 17134088)
5. Pettit, G.R., Singh, S.B., Niven, M.L., Hamel, E., Schmidt, J.M. Isolation, structure, and synthesis of combretastatins A-1 and B-1, potent new inhibitors of microtubule assembly, derived from Combretum caffrum. J Nat Prod 1987, 50(1): 119-31.
6. Pettit, G.R., Singh, S.B., Schmidt, J.M., Niven, M.L., Hamel, E., Lin, C.M. Isolation, structure, synthesis, and antimitotic properties of combretastatins B-3 and B-4 from Combretum caffrum. J Nat Prod 1988, 51(3): 517-27.
7. Pettit, G.R., Singh, S.B., Hamel, E., Lin, C.M., Alberts, D.S., Garcia-Kendall, D. Isolation and structure of the strong cell growth and tubulin inhibitor combretastatin A-4. Experientia 1989, 45(2): 209-11. (Pubitemid 19062390)
8. Zhu, H., Zhang, J., Xue, N., Hu, Y., Yang, B., He, Q. Novel combretastatin A- 4 derivative XN0502 induces cell cycle arrest and apoptosis in A549 cells. Invest New Drugs 2010, 28(4): 493-501.
9. Vitale, I., Antoccia, A., Cenciarelli, C. et al. Combretastatin CA-4 and combretastatin derivative induce mitotic catastrophe dependent on spindle checkpoint and caspase-3 activation in non-small cell lung cancer cells. Apoptosis 2007, 12(1): 155-66. (Pubitemid 46009511)
10. Liu, J.F., Fong, Y.C., Chang, K.W., Kuo, S.C., Chang, C.S., Tang, C.H. FPTB, a novel CA-4 derivative, induces cell apoptosis of human chondrosarcoma cells through mitochondrial dysfunction and endoplasmic reticulum stress pathways. J Cell Biochem 2011, 112(2): 453-62.
11. Terek, R.M., Schwartz, G.K., Devaney, K., Glantz, L., Mak, S., Healey, J.H., Albino, A.P. Chemotherapy and P-glycoprotein expression in chondrosarcoma. J Orthop Res 1998, 16(5): 585-90. (Pubitemid 28512438)
12. Greene, L.M., Nathwani, S.M., Bright, S.A. et al. The vascular targeting agent combretastatin-A4 and a novel cis-restricted {beta}-lactam analogue, CA-432, induce apoptosis in human chronic myeloid leukemia cells and ex vivo patient samples including those displaying multidrug resistance. J Pharmacol Exp Ther 2010, 335(2): 302-13.
13. Pattillo, C.B., Venegas, B., Donelson, F.J., Del Valle, L., Knight, L.C., Chong, P.L., Kiani, M.F. Radiation-guided targeting of combretastatin encapsulated immunoliposomes to mammary tumors. Pharm Res 2009, 26(5): 1093-100.
14. Chua, M.S., Sun, H., Cheung, S.T. et al. Overexpression of NDRG1 is an indicator of poor prognosis in hepatocellular carcinoma. Mod Pathol 2007, 20(1): 76-83. (Pubitemid 44967952)
15. Ohno, T., Kawano, K., Sasaki, A., Aramaki, M., Tahara, K., Etoh, T., Kitano, S. Antitumor and antivascular effects of AC-7700, a combretastatin A-4 derivative, against rat liver cancer. Int J Clin Oncol 2002, 7(3): 171-6. (Pubitemid 34733483)
16. Morinaga, Y., Suga, Y., Ehara, S., Harada, K., Nihei, Y., Suzuki, M. Combination effect of AC-7700, a novel combretastatin A-4 derivative, and cisplatin against murine and human tumors in vivo. Cancer Sci 2003, 94(2): 200-4. (Pubitemid 36575881)
17. Hori, K. Antineoplastic strategy: Irreversible tumor blood flow stasis induced by the combretastatin A-4 derivative AVE8062 (AC7700). Chemotherapy 2005, 51(6): 357-60. (Pubitemid 41546713)
18. Hori, K., Nishihara, M., Shiraishi, K., Yokoyama, M. The combretastatin derivative (Cderiv), a vascular disrupting agent, enables polymeric nanomicelles to accumulate in microtumors. J Pharm Sci 2010, 99(6): 2914-25.
19. Hori, K., Saito, S. Microvascular mechanisms by which the combretastatin A-4 derivative AC7700 (AVE8062) induces tumour blood flow stasis. Br J Cancer 2003, 89(7): 1334-44. (Pubitemid 37363426)
20. Tozer, G.M., Prise, V.E., Wilson, J. et al. Mechanisms associated with tumor vascular shut-down induced by combretastatin A-4 phosphate: Intravital microscopy and measurement of vascular permeability. Cancer Res 2001, 61(17): 6413-22. (Pubitemid 32785286)
21. Hori, K., Saito, S., Sato, Y., Akita, H., Kawaguchi, T., Sugiyama, K., Sato, H. Differential relationship between changes in tumour size and microcirculatory functions induced by therapy with an antivascular drug and with cytotoxic drugs. Implications for the evaluation of therapeutic efficacy of AC7700 (AVE8062). Eur J Cancer 2003, 39(13): 1957-66. (Pubitemid 37311194)
22. Hori, K., Saito, S., Kubota, K. A novel combretastatin A-4 derivative, AC7700, strongly stanches tumour blood flow and inhibits growth of tumours developing in various tissues and organs. Br J Cancer 2002, 86(10): 1604-14. (Pubitemid 34628115)
23. Shaked, Y., Tang, T., Woloszynek, J. et al. Contribution of granulocyte colony-stimulating factor to the acute mobilization of endothelial precursor cells by vascular disrupting agents. Cancer Res 2009, 69(19): 7524-8.